Schwabe Arthur D., Terasaki Paul I., Barnett Eugene V., Territo Mary C., Klinenberg James R., Peters Robert S.
West J Med. 1977 Jul;127(1):15-23.
The success of colchicine therapy in the management of familial Mediterranean fever has provided new direction to investigations into the pathogenesis of this disease. Examination of HLA antigen frequencies in 53 patients with familial Mediterranean fever and appropriate controls, as well as various immunologic studies have yielded no significant differences. However, B lymphocyte typing and assays for immune complexes, lymphokines and prostaglandins may be of potential interest. Preliminary studies indicate that leukocytes of patients with familial Mediterranean fever release increased amounts of lysozyme (P<0.01), when subjected to high temperatures, and of both lysozyme and myeloperoxidase at low osmotic concentrations. The known and potential effects of colchicine on leukocyte and cellular metabolism, and the current status of colchicine prophylaxis are reviewed. In patients receiving an optimum colchicine dose of 1.5 to 1.8 mg per day, side effects have been minimal and the frequency of attacks has been decreased significantly.
秋水仙碱疗法在家族性地中海热治疗中的成功为该疾病发病机制的研究提供了新方向。对53例家族性地中海热患者及相应对照进行HLA抗原频率检测以及各种免疫学研究，均未发现显著差异。然而，B淋巴细胞分型以及免疫复合物、淋巴因子和前列腺素检测可能具有潜在意义。初步研究表明，家族性地中海热患者的白细胞在高温下会释放更多溶菌酶（P<0.01），在低渗浓度下则会释放溶菌酶和髓过氧化物酶。本文综述了秋水仙碱对白细胞和细胞代谢的已知及潜在影响，以及秋水仙碱预防的现状。在接受每日1.5至1.8毫克最佳秋水仙碱剂量的患者中，副作用极小，发作频率显著降低。
